Company: MIRM
Filing Date: 2025-04-14
Form Type: DEF 14A
Source: 0001759425-25-000022
Chunk: 63

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-04-14
Form: DEF 14A
Chunk 63
---
il. |     |                |  68,750 |     |              | 149,989 |     |               | 149,774 |     |       | 368,513 |
| Timothy Walbert                 |     |                |  63,750 |     |              | 149,989 |     |               | 149,774 |     |       | 363,513 |

(1) The amounts reported here do not reflect the actual economic value realized by our directors. In accordance with SEC rules, this column represents the grant date fair value of shares underlying restricted stock units, calculated in accordance with FASB ASC 718. As of December 31, 2024, each of our non-employee directors held restricted stock units representing 5,703 shares of our common stock.

(2) Amounts shown in this column do not reflect dollar amounts actually received by non-employee directors. Instead, these amounts reflect the aggregate grant date fair value of each stock option granted computed in accordance with the provisions of FASB ASC Topic 718. Assumptions used in the calculation of these amounts are included in Note 12 to our consolidated financial statements included in the Annual Report. Our non-employee directors will only realize compensation to the extent the trading price of our common stock is greater than the exercise price of such stock options. As of December 31, 2024, Ms. Brege held options to purchase 90,946 shares of our common stock; Dr. Cardon held options to purchase 49,862 shares of our common stock; Mr. Fairey held options to purchase 72,529 shares of our common stock; Dr. Fischer held options to purchase 120,529 shares of our common stock; Mr. Grey held options to purchase 770,455 shares of our common stock; Mr. Heron held options to purchase 76,779 shares of our common stock; Ms. Ramasastry held options to purchase 62,279 shares of our common stock, 59,779 of which were granted to Ms. Ramasastry in connection with her service on the Board and 2,500 of which were granted to Ms. Ramasastry as compensation for services performed prior to her appointment to the Board; and Mr. Walbert held options to purchase 44,196 shares of our common stock.

Our Board adopted a non-employee director compensation policy in July 2019 that is applicable to all of our non- employee directors. The compensation policy was